SALT LAKE CITY — Denali Therapeutics is advancing the fight against neurodegenerative diseases thanks to pioneering work in methods to carry medicines across the blood-brain barrier, a critical ...

Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $33.33. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -4.62 and a beta of 1.58.

US-based biotechnology company Denali Therapeutics has reported that a Phase II/III trial of DNL343 for amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint. The primary ...

Norges Bank bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC.

Get the next trade alert free. Denali Therapeutics, Inc. DNLI shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of ...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

A 12-year, $1.5 billion push to develop drugs for rare genetic diseases led Denali Therapeutics Inc. to ask regulators Wednesday to approve its first drug, a treatment for a rare, life-shortening ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Denali Therapeutics vice president of clinical manufacturing Leah Frautschy, center, cuts a ribbon opening Denali Therapeutics' new biomedical facility in Salt Lake City on Thursday, March 27, 2025.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...